Form 4: ImmuCell Director Receives Stock Option Grant

Director Gloria F. Basse was granted 11,933 non-qualified stock options as compensation for board service.

Summary

• Director Gloria F. Basse received a grant of 11,933 non-qualified stock options on April 15, 2026.
• The options have an exercise price of $7.60 per share.
• The grant is part of the standard compensation package for board members of ImmuCell Corporation.
• The options vest in three tranches: 3,977 shares on April 15, 2027, 3,977 shares on April 15, 2028, and 3,979 shares on April 15, 2029.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment for investors.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.
• Standardized compensation structure indicates stable corporate governance practices.

Negatives

• Results in potential future dilution of existing shareholders upon exercise of the options.

Risks

• Market price volatility may impact the future value of the granted options.
• The exercise price of $7.60 may be higher or lower than the future market price, affecting the incentive value for the director.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on director compensation.

Management Comments

• The options were granted by the issuer to compensate directors for services on the Issuer's board of directors.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard practice in the biotechnology and pharmaceutical sectors to ensure alignment between leadership and long-term corporate performance.

Comparison to Industry Standards

• The use of multi-year vesting schedules (2027-2029) is consistent with standard corporate governance practices for retaining board members.
• Granting non-qualified stock options is a common method for small-cap biotech firms to preserve cash while incentivizing directors.

Stakeholder Impact

• Minor potential dilution for existing shareholders upon future exercise of options.

Next Steps

• Vesting of the first tranche of options on April 15, 2027.

Key Dates

Keywords

ImmuCell, ICCC, Director Compensation, Stock Options, Insider Transaction, Form 4